Archives

by in
Entry Author Date Location
ARCH Venture Exploits IPO Window To Raise $400M Fund, Its Eighth 08/27/14 Seattle
Coelacanths And Other IPO Thoughts Before The Autumn Markets Return 08/26/14 National
East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More 08/15/14 Boston
East Coast Biotech Roundup: Bluebird, Moderna, Navitor, & More 06/20/14 Boston
Two San Francisco Startups Sharing In Third Rock’s Rich Third Fund 04/24/14 San Francisco
East Coast Biotech Roundup: Agios, Spero, Cerulean, & More 04/11/14 Boston
Agios Taps Wall Street Off Early Data, Aims For $75M 04/10/14 Boston
Agios’s Blood Cancer Drug Shines in First Clinical Test 04/06/14 Boston
Backed By a Billionaire, Berg Pharma Aims to Speed Drugmaking 04/02/14 Boston
Calithera Targets Otherworldly Metabolism of Tumor Cells 03/18/14 San Francisco
East Coast Biotech Roundup: Genocea, Eleven, NIH/Pharma, & More 02/07/14 Boston
Xconomy Boston’s Top 10 Stories of Q4: Editor’s Picks 12/30/13 Boston
East Coast Biotech Roundup: ASH, Proteostasis, Retrophin, & More 12/13/13 Boston
East Coast Biotech Roundup: Juno, Editas, Celgene, & More 12/06/13 Boston
Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell Drugs 12/03/13 San Francisco
3 Life Sciences Companies That Are Built to Last 12/02/13 National
Calithera BioSciences Nabs $35M for Cancer Drugs 10/29/13 San Francisco
East Coast Biotech Roundup: Schenkein, PureTech/JDRF, Sage, & More 10/18/13 Boston
Sage Therapeutics Nabs $20M Series B From Third Rock, Arch 10/16/13 Boston
David Schenkein, Cancer Doc Turned CEO, Aims to Build New Genentech 10/16/13 Boston
East Coast Life Sciences Roundup: Foundation, Ophthotech, Sato, & More 09/27/13 Boston
Foundation Medicine Scores $106M in Upsized IPO 09/24/13 Boston
Acceleron Prices Upsized IPO at $15 Per Share, Begins Trading Thursday 09/19/13 Boston
Which VCs Are Poised to Profit From the Biotech IPO Boom? 09/09/13 National
Biotech and Fantasy Football Picks for Fall 2013 09/03/13 National
Epizyme Execs Share the Secret to a Successful IPO: PowerBars 08/15/13 Boston
East Coast Life Sciences Roundup: KiiLN, Celgene, Acceleron, & More 08/09/13 New York
Celgene Partner Acceleron Files For IPO; Plans to Raise Up to $75M 08/07/13 Boston
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
Foundation Medicine Lays Groundwork For $86M IPO 07/29/13 Boston
Page 1 of 3 next page »